Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency
Scope’s report finds biologics likely to be protected from severe biosimilar erosion but sees warning signs for the generics industry.
Scope’s report finds biologics likely to be protected from severe biosimilar erosion but sees warning signs for the generics industry.
As we move closer to the end of the year, companies are assembling their boardrooms ready for the new year.